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Review of the Melanoma Cases Treated at Lehigh Valley Health Network in 2013
Kelly Cann, Savitri P. Skandan, MD
Lehigh Valley Health Network, Allentown, Pennsylvania

Introduction

Results

Melanoma of the skin is estimated to be the 5th most
common cancer in the US in 2014 and among the top 5
most common types of cancer diagnosed at LVHN in
2013.1
It is estimated that by the end of 2014 there will have been
76,100 patients diagnosed with melanoma and 9,710
melanoma related deaths.1
Diagnosing melanoma in the early stages is the key to Table 1: Staging of 128 skin and scalp melanoma patients diagnosed and treated at
Lehigh Valley Health Network in 2013.
better prognosis. The survival rates are 98% for
localized melanoma, 62% for regional melanoma, and
16% for distant melanoma.1
The BRAF gene encodes a serine-threonine protein kinase
which acts in a pathway that regulate cell proliferation and
growth. When BRAF is mutated, cell growth is no longer
regulated properly which leads to tumor cell proliferation,
invasion, and resistance. BRAF mutation is commonly
found in aggressive cancers.2
The purpose of our study is to determine if treatment
provided for skin and scalp melanoma at LVHN in 2013
Figure 1: Treatment received for stage 0 melanoma in situ and stage 1 melanoma
was in accordance with the treatment described in the
at Lehigh Valley Health Network in 2013. Surgery can include wide excision,
NCCN Guidelines. We also wanted to investigate if there reexcision, and sentinel lymph node biopsy.
was a positive correlation between patients with
metastatic melanoma to the brain and a BRAF mutation.

Methods
 137 melanoma cases seen at LVHN during 2013 were
screened. Mucosal melanomas, cases with unknown
staging, cases with no follow up, and cases with
pathology not indicative of melanoma were excluded,
leaving 128 cases to be reviewed.
Age, gender, stage, treatment, presence of brain
metastasis, presence of BRAF mutation, and patient
mortality were determined by reviewing all patient
records including radiology and pathology results done
during 2013.
The National Comprehensive Cancer Network Clinical
Practice Guidelines in Oncology for Melanoma Version
4.2014 was used as a standard for comparing the
treatments patients at LVHN received to the treatments
outlines in the NCCN Guidelines.

Figure 3: Stage 4 melanoma patients treated at LVHN in 2013 that were tested
for BRAF mutation(V600E) and brain metastasis. Excluded from this figure is one
stage 3 melanoma patient that tested positive for the BRAF mutation, 2 cases
where stage 4 patients were not tested for brain metastasis or the BRAF
mutation, and 3 cases where patients were negative for brain metastasis and
were not tested for the BRAF mutation.

Conclusions
The majority of patients presented with stage 1
melanoma on diagnosis.
The majority of patients were males over age 50 at the
time of diagnosis.
50% of stage IV patients tested for the BRAF mutation
were BRAF positive.
75% of stage IV patients with brain metastasis that were
tested for the BRAF mutation were BRAF positive.
The average age at diagnosis for BRAF positive patients
was 56 years, in comparison to 63 years for BRAF wild
type patients which is consistent with the literature which
states that BRAF mutation is more common in younger
patients at diagnosis.3
Treatments recommended/received for melanoma at
LVHN in 2013 were in accordance with the NCCN
Guidelines version 4.2014.4
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